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Probenecid-Boosted Tenofovir: A Physiologically-Based 
Pharmacokinetic Model-Informed Strategy for  
On-Demand HIV Preexposure Prophylaxis
Stephanie N. Liu1, Zeruesenay Desta1,* and Brandon T. Gufford1
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV preexposure prophy-
laxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by or-
ganic ion transporters (OATs; OAT1 and OAT3). Using in vitro kinetic parameters for TFV and the OAT1 and OAT3 inhibitor 
probenecid, a bottom-up physiologically-based pharmacokinetic model was successfully developed for the first time that 
accurately describes the probenecid–TFV interaction. This model predicted an increase in TFV plasma exposure by 60%, 
which was within 15% of the observed clinical pharmacokinetic data, and a threefold decrease in renal cells exposure fol-
lowing coadministration of a 600 mg TDF dose with 2 g probenecid. When compared with multiple-dose regimens, a single-
dose probenecid-boosted TDF regimen may be effective for HIV PrEP and improve adherence and safety by minimizing 
 TFV-induced nephrotoxicity by reducing TFV accumulation in renal cells.
Tenofovir disoproxil fumarate (TDF), in combination with 
emtricitabine, is an effective oral therapy for the preven-
tion of new HIV infections. In 2016, a nondaily on-demand 
therapy of TDF from the IPERGAY study showed promising 
effects for HIV preexposure prophylaxis (PrEP) comparable 
to daily administration.1 Although effective, this on-demand 
regimen relies on adherence to intermittent drug admin-
istration both before and after sexual activity. Perhaps of 
more practical importance, sexually active individuals (> 2 
sexual encounters per week) would require nearly daily 
drug administration to maintain protection. Poor adher-
ence, especially in the setting of participants not currently 
in a monogamous relationship, has been suggested as a 
possible reason why some multiple day treatments may 
have failed in preventing HIV infections. As such, methods 
to improve adherence to PrEP regimens with oral antiret-
rovirals in HIV-negative individuals would be of great value 
to the HIV community at large.2 Reported reasons for non-
adherence from patients include pill burden, cost, and 
long-term adverse events,3 so perhaps a single-dose HIV 
PrEP regimen with TDF may be a solution.
TDF, a potent antiretroviral for PrEP, rapidly releases teno-
fovir (TFV) following oral administration that subsequently is 
eliminated from the body entirely by the kidneys. Part of this 
elimination process involves active secretion of TFV by uptake 
renal organic anion transporters (OATs; OAT1 and OAT3). TFV 
may also be distributed into cells by unknown mechanisms 
where it is available for phosphorylation to the active moiety 
tenofovir di-phosphate, TFV-DP. The polarity of TFV-DP causes 
“ion-trapping” inside cells and results in TFV-DP accumulation 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Tenofovir disoproxil fumarate (TDF), in combination 
with emtricitabine, is used for HIV preexposure prophy-
laxis (PrEP). TDF is rapidly hydrolyzed to tenofovir (TFV) in 
plasma. TFV is a substrate for renal secretion via organic 
anion transporters (OATs; OAT1 and OAT3). Probenecid 
(PRO) is a potent inhibitor of OAT1 and OAT3.
WHAT QUESTION DID THE STUDY ADDRESS?
✔  This work developed a physiologically-based pharma-
cokinetic (PBPK) model-informed predictive tool for the 
transporter-mediated drug–drug interaction (DDI) between 
TFV and PRO in plasma to be used for on-demand HIV PrEP.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  An accurate PBPK model describing the transporter- 
mediated DDI between TFV and PRO in plasma was  developed 
and predicted TFV plasma maximum concentration (Cmax) 
and area under the curve from zero to infinity (AUC0−INF) 
within 15% of observed after a single dose of 600 mg TDF.
HOW MIGHT THIS CHANGE CLINICAL PHARMA- 
COLOGY AND THERAPEUTICS?
✔  This model-informed strategy serves as a useful pre-
dictive tool to inform clinical study design and accurately 
predict the impact of PRO on TFV pharmacokinetics to 
optimize TDF efficacy and safety.
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and longer exposure compared with the moiety found in cir-
culation, TFV. For example, with daily TDF administration, the 
accumulation of the TFV-DP in the lymphocytes (peripheral 
blood mononuclear cells (PBMCs)) is greater than eightfold.4 
Although this accumulation provides beneficial protection from 
HIV acquisition in the PBMCs, it may lead to nephrotoxicity in 
kidney cells. Probenecid (PRO) is a well-tolerated oral drug 
that blocks renal organic anion transporters (OATs) located on 
the basolateral side of the renal cell. By doing so, taking PRO 
with TDF would be expected to reduce the renal elimination of 
TFV and thereby increase the length of time that TFV remains 
active in the body. Thus, the administration of TDF with PRO 
may allow less-frequent dosing of TDF and reduce the harmful 
exposure of the drug to the kidneys.
Physiologically-based pharmacokinetic (PBPK) models can 
be used as predictive tools for drug–drug interactions (DDIs), 
particularly for small molecules such as TFV. They have been 
used commonly in predicting both the impact of drug inhibition 
on substrate pharmacokinetics and informing clinical study 
designs.5,6 In some cases, PBPK models are used in lieu of 
clinical pharmacokinetic data for dosing recommendations 
and product labeling.6 Traditionally, DDI PBPK models were 
developed for enzyme-mediated interactions, but as our under-
standing of transporter-mediated drug disposition advances, 
transporter-mediated models are also being studied.5 In this 
proposal, a PBPK model was developed to predict the effects 
of the transporter-mediated DDI between PRO and TFV for a 
single-dose HIV PrEP regimen. In this model-informed strategy 
for on-demand HIV PrEP, a PRO-boosted TFV PBPK model 
was used to prospectively optimize PRO dosing for a clinical 
study design based on in vitro TFV and PRO parameters. Then 
retrospectively, the simulated DDI pharmacokinetic parameters 
were compared with available observed data to assess model 
performance. The model used extravascular compartments in-
cluding PBMCs and renal cells for the surrogate interpretations 
of TFV efficacy and nephrotoxicity, respectively.
The objectives of the current analyses were to (i) develop and 
verify PBPK models that accurately described TFV and TFV-DP 
plasma and PBMC pharmacokinetic profiles, (ii) simulate pro-
spective DDIs between PRO and TFV that may be applicable for 
use as an on-demand PrEP regimen, (iii) retrospectively evaluate 
DDI predictions with observed data, and (iv) assess the impact 
of coadministered PRO on TFV renal exposure and toxicity.
METHODS
The model flow for this article is shown in Figure 1.
Model development and verification
TFV substrate model. The base PBPK model in plasma was 
adapted from a previously published model of TFV exposure 
in pregnancy7 and modified with supporting literature.8–15 The 
PBPK model was built using SimCYP (version 15; Certara, 
Inc., Princeton, NJ). Briefly, the published TFV base model 
was a first-order absorption, full distribution, permeability-
limited kidney PBPK model. The B:P ratio was updated from 
more accurate information available for TFV alafenamide 
under the assumption that there would be no changes in 
this parameter for TFV.9 It was then enhanced by adding 
mechanistic description of OAT-mediated TFV uptake in 
the kidney via both OAT1 and OAT3 and MRP4-mediated 
efflux.13–15 Renal clearance in SimCYP is calculated using the 
following equation: 
where Clr is renal clearance of drug for individual, Qr is 
renal blood flow, CLUsec,int is active secretion of drug, GFR 
is glomerular filtration rate for individual, and Fre–abs is the 
Clr=Qr×
[
fu×GFR
Qr
×
(
1−
fu×GFR
Qr
)
×
(
Qr× fu×CLUsec ,int
Qr+ fu×CLUsec ,int
)]
×
(
1−Fre−abs
)
,
Figure 1 Proposed drug–drug interactions (DDI) physiologically-based pharmacokinetic (PBPK) model workflow. *A randomized, 
cross-over, two-treatment clinical study conducted in healthy volunteers for the treatments predicted by DDI PBPK model were 
evaluated: (i) Test treatment: 600 mg tenofovir disoproxil fumarate (TDF) + 2 g probenecid (PRO) on day 1; (ii) control treatment: 600 mg 
TDF on day 1, 300 mg TDF day 2, 3. TFV, tenofovir.
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fractional tubular reabsorption.16 The PBPK model input pa-
rameters are shown in Table 1. The clinically observed data 
for oral 300 mg TDF dosing in healthy volunteers reported 
by Wenning et al.17 was retrieved by the GetData Graph 
Digitizer (version 2.26.0.20; GetData Pty Ltd., Kogarah, 
Australia) and used as a verification set for the TFV base 
model. The base model was further expanded to describe 
the active TFV-DP concentrations in PBMCs using previ-
ously published kinetic parameters to describe the rate 
of uptake and efflux of TFV-DP into these cells.11,12 This 
was described as an additional organ compartment with 
parameters shown in Table 1. The model was able to ade-
quately predict clinically observed TFV-DP concentrations 
in PBMCs at steady state in healthy volunteers.11
PRO inhibitor model. The “boosting” effects of PRO were 
evaluated using the verified SimCYP library PBPK model 
and incorporating modified inhibition potencies toward 
OAT1-mediated and OAT3-mediated renal uptake of TFV.18,19 
The modified inhibitory input parameters are shown in Table 1. 
This approach has been previously used to accurately 
predict the impact of PRO interactions with the antiinfective 
agents cidofovir, oseltamivir, and cefuroxime.20
DDI model predictions and evaluation
The initial models developed previously for TFV (substrate) 
and PRO (inhibitor) were combined in the DDI model and 
used for dynamic predictions of PRO inhibitory effects on 
TFV plasma and TFV-DP PBMC pharmacokinetics. First, 
the model was used to optimize the dose of PRO for maxi-
mum boosting effects on single-dose TFV for HIV PrEP. Next, 
trial designs and drug administration identical to observed 
(Figure S1) were simulated and compared retrospectively 
when information became available. The dose-optimized 
PRO-TFV PBPK model was used to predict pharmacokinetic 
parameter changes of a single 600 mg TDF dose in the pres-
ence and absence of 2  g PRO. Similarly, the PBPK model 
was then used to predict multiple doses of TDF seen in the 
IPERGAY study. Briefly, the IPERGAY study drug administra-
tion was a 3-day medication course of 600 mg TDF on day 
1, followed by doses of 300 mg TDF on days 2 and 3. Both 
predicted clinical scenarios were compared with observed 
data from healthy volunteers.21 Single-dose TFV pharmaco-
kinetic parameters in the presence and absence of 2 g PRO 
from the clinical study were recovered by noncompartmen-
tal analysis performed by Phoenix WinNonlin (version 6.4; 
Certara, Inc.). More information on the study design is pro-
vided in the Supplemental Information. The single-dose 
DDI predictions were evaluated for accuracy through visual 
predictive checks and pharmacokinetic parameters: max-
imum concentration (Cmax) geometric mean ratio (GMR; 
GMR + PRO/−PRO), and area under the curve (AUC) GMR, 
and renal clearance (Clr). If the pharmacokinetic parameters 
were within twofold of the observed and the observed data 
overlay within the 95% confidence intervals of predicted TFV 
concentration-time profiles, the model was considered ac-
curate. For intracellular TFV-DP PBMC concentrations and 
multiple-dose TFV simulations, the models were evaluated 
by visual predictive checks only. Finally, the PBPK model was 
used to predict the effects of PRO on TFV exposure in renal 
cells. The mechanistic kidney model within the SimCYP sim-
ulator was selected to evaluate the different kidney processes 
(i.e., filtration and secretion) contributing to TFV renal clear-
ance with or without PRO.
Trial design simulations
Initially, the TFV base model was developed in a single trial 
with 14 healthy volunteers. Next, trial simulations of 10 trials 
with 14 healthy volunteers for a total population size of 140 
were simulated and selected for model performance (verifi-
cation and evaluation data sets). The multiple trial predicted 
mean (and 95% confidence intervals) for plasma and PBMC 
concentration-time profiles are shown in the figures.
Sensitivity analysis
Sensitivity analysis was performed by the automated 
sensitivity analysis tool within SimCYP. Input parameters 
chosen for sensitivity analysis include PRO OAT1 and OAT3 
Table 1 SimCYP input parameters for TFV (substrate) and PRO 
(inhibitor)
TFV parameter Input
MW 2877
logP 1.258
B/P 19
pKa 3.758
fu 0.93
8
fa 0.2
8
ka 1.03 1/h
11
Absorption
Simulation 1st order7
LLC-PK1 265 10−6 cm/second7
Distribution
Simulation Full PBPK
Vss 0.307 L/kg (method 2)
10
Transport (elimination)
CLPD (hepatic) 4 × 10-5 mL/minute/10
−6 cells6
Sinusoidal uptake (Clint) 
(hepatic)
3.125 mL/minute/10−6 cellsa 
OAT1 transporter (Clint) (renal) 5.8 µL/min/10
−6 cells13–15
OAT3 transporter (Clint) (renal) 3.6 µL/minute/10
−6 cells13–15
MRP4 transporter (Clint) (renal) 1 µL/minute/10
−6 cells15
PBMC (additional organ PD)
Uptake Jmax 10.44 pmol/minute/whole organ
11,12
Uptake Km 0.355 µM
11,12
Efflux Clint,t 1.288 µL/minute
11,12
PRO parameterb Input
OAT1 Transporter (Ki) (renal) 4.03 µM
18,19
OAT3 Transporter (Ki) (renal) 1.3 µM
18,19
B/P, blood to plasma ratio; Clint, intrinsic clearance; CLPD, passive diffu-
sion clearance; fa, fraction absorbed; fu, fraction unbound; Jmax, maximum 
transporter rate; ka, absorption rate constant; Ki, inhibitor rate constant; 
Km, Michaelis-Menten constant; logP, partition coefficient; MW, molecular 
weight; PBMC, peripheral blood mononuclear cells; PBPK, physiologically-
based pharmacokinetic; pKa, dissociation constant; PRO, probenecid; 
TFV, tenofovir; Vss, volume at steady-state.
aOptimized to fit observed data by automatic sensitivity analysis in SimCYP.
bSimCYP library model was used for PRO with the additional modifications.
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inhibitor rate constant (Ki) and TFV OAT1 and OAT3 intrinsic 
clearance (Clint).
RESULTS
Base model verification and PRO dose optimization
Initial TFV model development. Predicted TFV and TFV-
DP concentration-time profiles for a single dose of 300 mg 
TDF in the plasma and PBMC, respectively, are shown in 
Figure 2. The visual predictive checks for both TFV and 
TFV-DP were accurate. Notably, large variability was seen 
in the observed TFV-DP concentrations. The simulated TFV 
plasma model also produced pharmacokinetic outcomes 
comparable with published data (Table S1).
Initial PRO-TFV model development. To optimize dose 
selection of PRO for the clinical study based on its in vitro 
OAT1 and OAT3 inhibitory effects, the DDI was simulated 
with both 1 and 2 g of PRO. The effects of 1 g or 2 g PRO 
boosted on TFV pharmacokinetic parameters are shown in 
Table 2. Coadministration of PRO with TDF predicted 45% 
and 60% increases in overall plasma exposure when given 
with 1 and 2 g dose of PRO, respectively. The 2 g dose of 
PRO was selected for the clinical study design because 
higher TFV exposure was predicted and 2 g is considered 
the maximum tolerated dose for PRO22 and thus more suit-
able for single-dose boosting effects.
PRO-TFV DDI model evaluation
PRO-TFV plasma model. After the clinical study was 
completed, the predicted single-dose 2 g PRO-boosted TFV 
and multiple-dose IPERGAY TFV plasma concentration-
time profiles were retrospectively compared with observed 
data (Figure 3). Visual predictive checks were accurate for 
the single-dose regimen of TFV but tended to underpredict 
concentrations after 24  hours. Multiple-dose TFV trough 
concentrations were similarly underpredicted at 24, 48, and 
72  hours. Considering TDF is dosed every 24  hours and 
concentrations immediately prior to subsequent dosing was 
inaccurate, this suggests that the model may underpredict 
observed drug accumulation. The single-dose effects of 
PRO on TFV pharmacokinetic parameters in predicted and 
observed data are shown in Table 3. In the presence of 
2 g PRO, single-dose TFV overall exposure area under the 
curve from zero to infinity (AUC0-INF) increased by 60% and 
Cmax was nearly unchanged as predicted.
PRO-TFV PBMC model. Evaluations of the predicted TFV-
DP concentrations in both regimens is shown in Figure S2. 
When compared with the observed data, simulated TFV-DP 
concentrations were overpredicted, although the slow trend 
of TFV-DP accumulation after multiple doses was captured 
in the model.
TFV in renal cells. The predicted amount of TFV in renal 
cells over time is shown in Figure 4 and Table S2. The 
overall amount of TFV excreted over 72  hours remained 
unchanged in the presence of PRO. However, the maximum 
amount of TFV in renal cells was predicted to decrease by 
nearly threefold when given with PRO.
Sensitivity analysis
Sensitivity analysis was performed for TFV OAT1 and OAT3 
Clint (Figure S3) and PRO OAT1 and OAT3 Ki (Figure S4). 
Effects on the TFV pharmacokinetic parameters (AUC0-INF 
GMR, Cmax GMR, and Clr) are shown. Independent to input 
value (>  0), TFV renal secretion mediated via OAT1 and 
OAT3 Clint were contributors for the change in TFV AUC 
Figure 2 Concentration-time profile of single oral dose 300  mg tenofovir disoproxil fumarate predicted by physiologically-based 
pharmacokinetic model in the plasma—tenofovir (TFV) (a) and peripheral blood mononuclear cells—tenofovir di-phosphate (TFV-DP) 
(b) overlaid by clinical observed data (Liu et al.21). The black open circles represent the observed data. Black solid lines represent the 
predicted and black dash lines show the predicted 5th and 95th confidence intervals. h, hour.
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Table 2 PBPK model predictions for PRO 1 and 2 g dose projections 
on TFV pharmacokinetic parameters in plasma
TFV PK parameter 1 g PRO 2 g PRO
AUC0-INF with inhibitor, 
ng • hour/mL
5,064 (4,808–5,287) 5,617 (5,290–5,964)
AUC0-INF GMR 1.46 (1.36–1.57) 1.59 (1.55–1.64)
Cmax with inhibitor, 
ng/mL
546 (517–574) 566 (535–600)
Cmax GMR 1.11 (1.10–1.12) 1.13 (1.12–1.14)
Data represented as GM (95% confidence interval).
AUC0-INF, area under the curve from zero to infinity; Cmax, maximum con-
centration; GM, geometric mean; GMR, geometric mean ratio; PBPK, 
physiologically-based pharmacokinetic; PK, pharmacokinetics; PRO, 
probenecid; TFV, tenofovir. 
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GMR with PRO coadministration. TFV OAT1 and OAT3 Clint 
had a minimal effect on Cmax GMR, as expected. Renal 
clearance for TFV (Clr) directly correlated with TFV OAT1 
and OAT3 Clint. Ki of PRO for the inhibition of OAT1 and 
OAT3 had impacts on AUC0-INF GMR and Cmax GMR, 
whereas this inhibition constant had no impact on overall 
TFV renal function, Clr.
DISCUSSION
This work is the first to publish a PBPK model to describe 
the transporter-mediated interaction between TFV and 
PRO. This was also the first attempt to simulate the dispo-
sition of the antiretroviral in the renal cells and at the site of 
action (PBMCs) using a PBPK model.
Recently, a PBPK model for TFV and PRO was published 
as an OAT1 and OAT3 substrate and inhibitor, respectively, 
and studied for DDIs with a new molecule in drug develop-
ment.23 The in vitro parameters for TFV were similar to ours, 
but PRO in vitro inhibitory constants varied, and the model 
underpredicted PRO effects on the new molecule in vivo.23 
In our work, the inhibition model for PRO was optimized 
from its effect on other molecules with similar pharmaco-
kinetics.20 PRO has been studied previously in conjunction 
with other antiinfective agents, particularly those with a 
high propensity for renal secretion. In addition to the drug 
pharmacodynamics profile being directly linked to their 
pharmacokinetic parameters (i.e., AUC to MIC, Cmax to MIC), 
such pharmacokinetic properties make them excellent can-
didates for PRO boosting. For example, penicillin is a known 
OAT substrate and prescribed in combination with PRO as a 
boosting strategy for prolonged antibacterial coverage and 
serious infections such as meningitis.24 There is great ben-
efit to providing an accurate base PBPK model to predict 
the mechanistic interaction between antiinfectives and PRO. 
Our work with TFV and PRO may serve as a prototype for 
this concept.
Our accurate PBPK model predicted DDI effects between 
PRO and TFV in plasma (Cmax and AUC0-INF) within 15% of 
observed. A single dose of 2  g PRO increased TFV over-
all plasma exposure by 60%. Our clinical study and the 
PBPK model in this article evaluated the drug exposure of 
TFV in fasted healthy volunteers. Other studies found that 
TDF given with high-fat or light meals increases TFV sys-
temic exposure by ~  35%. Thus, the inhibitory effects of 
PRO along with the food effect may result in much higher 
exposure of TFV than is predicted using fasting conditions. 
The change observed in TFV exposure from PRO alone cor-
relates well with the drug’s ADME properties, making it a 
suitable agent for the mechanistic underpinnings in a PBPK 
model. TFV has low bioavailability (~ 25%), high fraction un-
bound (fu > 0.9) and is entirely cleared by the kidneys with 
no known enzyme metabolism involvement.25–27 TFV is 
eliminated through both renal filtration and active secretion 
via influx-mediated OAT1 and OAT3 and efflux-mediated 
MRP4 transporter involvement.13,15 Because TFV is highly 
unbound in the blood, a greater portion of its clearance is 
perhaps through glomerular filtration. Only 20–30% of TFV in 
Figure 3 Plasma concentration-time profiles of single-dose probenecid-boosted tenofovir (TFV) (a) and on-demand IPERGAY TFV (b) 
predicted by physiologically-based pharmacokinetic model and overlaid by clinical observed data (Liu et al.21). The black open circles 
in a and squares in b represent the observed data. Black solid lines represent the predicted and black dash lines show the 5th and 
95th confidence intervals. h, hour.
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Table 3 Retrospective evaluation of PBPK model predicted TFV 
pharmacokinetic parameters to observed data
PK parameters PRED OBS
Fold 
change
SD TFV + PRO
CLr, L/hour 9.12 (8.78–9.48) 9.48 (7.29–12.3) 0.96
Cmax, ng/mL 566 (5,345–600) 538 (494–585) 1.05
AUC0-INF, ng • 
hour/mL
5,617 
(5,290–5,964)
6,349 
(5,598–7,200)
0.88
SD TFV–PRO
CLr, L/hour 14.6 (14.0–15.3) 15.4 (12.2–19.4) 0.95
Cmax, ng/mL 502 (473–533) 529 (451–620) 0.95
AUC0-INF, ng • 
hour/mL
3,521 
(3,302–3,756)
3,973 
(3,576–4,415)
0.89
Ratio
Cmax GMR 1.13 (1.12–1.14) 1 (0.91–1.1) 1.13
AUC0-INF GMR 1.59 (1.55–1.64) 1.6 (1.5–1.8) 0.99
Data represented as GM (95% confidence interval).
AUC0-INF, area under the curve from zero to infinity; CLr, renal clearance; 
Cmax, maximum concentration; GMR, geometric mean ratio; OBS, ob-
served; PBPK, physiologically-based pharmacokinetic; PRO, probenecid; 
PRED, predicted; SD, standard deviation; TFV, tenofovir.
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circulation is available for transporter-mediated secretion.27 
Thus, the inhibitory effects of PRO on the renal transporters 
OAT1 and OAT3 altered a considerable portion of TFV total 
apparent clearance as seen by the 60% change in AUC0-INF. 
Although PRO boosted TFV in plasma well, there were 
smaller changes at the intracellular level (~ 30% increase at 
24 hours)21 that were not accurately reflected in the PBPK 
model. In healthy volunteers, a single PRO-boosted TDF 
dose resulted in TFV-DP concentrations that stayed above 
the EC90 (16 fmol/10
6 cells) for more than 72 hours.28 This 
may be adequate coverage for single-dose HIV PrEP but re-
quires further study.
Although TDF is generally well tolerated, long-term 
adverse events have been associated with its use, which in-
clude nephrotoxicity29 and osteopenia.30 Tenofovir-induced 
renal proximal tubulopathy, or Fanconi syndrome, has been 
suggested as a potential mechanism leading to both ad-
verse events.29–31 By blocking entry of TFV into the renal 
proximal tubule, PRO use may limit the risk of renal tox-
icity by limiting TFV exposure to the proximal tubular cells 
without diminishing efficacy. In a case report, the PRO-
TDF combination was studied in three patients and found 
to be clinically beneficial.32 The HIV-infected patients were 
adequately treated for HIV infection and provided renal pro-
tection from Fanconi syndrome when coprescribed PRO 
and TDF.32 This model may serve as a clinical predictive 
tool for TFV-PRO use in these clinical scenarios where tai-
loring care is crucial for the relief of toxic adverse events. 
TDF-induced bone loss may also occur via alternative 
mechanisms, including increased TFV plasma exposure. 
However, these mechanisms are not expected to be ex-
acerbated by PRO boosting as overall plasma exposure is 
similar to that of previously evaluated regimens. In addition, 
any changes in renal function or bone mineral density as-
sociated with TDF use appear to be quickly reversible after 
TDF cessation, suggesting that TDF-based PrEP does not 
lead to permanent dysfunction.33,34 As expected, our model 
shows PRO inhibition of OAT-mediated TFV renal uptake 
reduced the amount of TDF exposure in the kidneys. Peak 
TFV kidney exposure following a PRO-boosted regimen is 
expected to be reduced on average by more than threefold 
when compared with the IPERGAY regimen, with a sub-
stantial reduction in overall exposure.
There is an increasing use of PBPK models for en-
zyme-mediated or transporter-mediated DDIs. PBPK models 
are especially touted for the ability to extrapolate beyond 
the data set available and in some cases be used in lieu of 
clinical data for product labeling, designing clinical studies, 
and first-in-human projections.6 Although CYP-mediated 
DDIs are common, transporter-mediated DDIs are less well 
studied because of the uncertainty in the human physiology 
of transporters and the general assumption that transport-
er-mediated DDIs have less clinically significant interactions. 
However, PRO can be a strong inhibitor for certain OAT1 and 
OAT3 substrates and evidently beneficial for some patients. 
An accurate PBPK model has been created for the sin-
gle-dose interaction between TFV and PRO in the systemic 
circulation. This model may serve to inform other OAT1 and 
OAT3 substrates under future investigation. In this context, 
the US Food and Drug Administration recommends new mo-
lecular entities with considerable renal clearance and shown 
to be in vitro OAT1 and OAT3 to be studied with PRO.35 In 
addition, this model also provides a mechanism-based eval-
uation for proximal tubule cell drug uptake. The developed 
PBPK model is a translational approach from in vitro TFV and 
PRO parameters to predict the underlying mechanistic and 
physiologic components of the interaction. In this work, the 
model was used as a predictive tool for the boosting effects 
of PRO on TFV for the exploration of a single-dose HIV pre-
vention regimen.
Often, model predictions correlated poorly to observed 
in the PBMC compartment, limiting its use for accurate 
quantitative predictions only to the plasma compartment. 
This may be in part because of the nonlinear kinetics of the 
TFV-DP in PBMCs after multiple doses. The rate of TFV-DP 
entering and leaving PBMCs is inconsistent and varies from 
a single dose to steady-state TDF administration.4 Because 
the model was developed using steady-state TFV-DP ad-
ministration, this may account for some of the inaccuracy in 
TFV-DP predictions because the TDF regimens evaluated 
Figure 4 Renal cell tenofovir (TFV) concentration-time profiles after (a) single-dose 600 mg tenofovir disoproxil fumarate (TDF) given 
with (black) or without (green) 2 g probenecid (PRO) and (b) on-demand HIV preexposure prophylaxis regimens as single-dose 2 g 
PRO-boosted 600 mg TDF (black) compared with the 3-dose IPERGAY (green) dosing regimen predicted by the physiologically-based 
pharmacokinetic model. h, hour. 
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in our work did not achieve steady-state levels. In addi-
tion, because the rates of TFV-DP kinetics in PBMCs were 
unavailable in healthy volunteers, the PBMC compartment 
in our model was generated using a data set derived from 
HIV-infected individuals. The plasma pharmacokinetics 
in healthy volunteers and HIV-1 infected individuals are 
thought to be similar. However, intracellular kinetics are 
generally less understood on a mechanistic level, which 
may require further study. In addition, the multiple-dose 
TFV plasma trough concentrations seen in the IPERGAY 
regimen were underpredicted. This is most likely attributed 
to the incorrect capture of TFV accumulation after multiple 
doses. TFV demonstrates biphasic elimination in vivo with a 
long distribution phase, probably because of the high frac-
tion unbound of TFV, making the drug available for tissue 
uptake. We think the model is misinterpreting the delayed 
elimination phase for the distribution phase and thus mis-
calculating the true elimination phase, although the impact 
of the DDI was still accurately predicted. This is an inherent 
limitation to our model and is difficult to resolve with the 
current modeling software and must be taken into account 
if applying this model to daily dosing.
In conclusion, this is the first attempt to model the effect 
of PRO on plasma TFV and intracellular exposure of its ac-
tive metabolite, TFV-DP, in the context of inhibition of renal 
transporters (OAT1 and OAT3). An accurate single-dose 
PRO-TDF PBPK model was developed. PRO boosted TFV 
plasma exposure by 60% and increased TFV-DP in PBMC 
by approximately threefold. Although further refinement 
would be required, this initial work suggests that a PBPK 
model can be used to evaluate the safety and efficacy of 
DDIs involving inhibition of OAT1 and OAT3.
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